RECURSION PHARMACEUTICALS, INC. Cost of Revenue
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Cost of Revenue of $11.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $11.49M, a 43.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $12.49M, a 42.78% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $14.28M, a 11.58% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $14.69M, a 21.59% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2025 was $70.95M, a 56.84% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $45.24M, a 6.22% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $42.59M, a 11.78% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $48.27M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.49M 10-Q · filed 2026-08-05 | $23.98M 10-Q · filed 2026-08-05 | $38.26M derived: sum of 3 quarters · filed 2026-08-05 | $52.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $12.49M 10-Q · filed 2026-05-06 | $26.77M derived: sum of 2 quarters · filed 2026-05-06 | $41.45M derived: sum of 3 quarters · filed 2026-05-06 | $61.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $14.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $28.96M derived: sum of 2 quarters · filed 2026-02-25 | $49.12M derived: sum of 3 quarters · filed 2026-08-05 | $70.95M 10-K · filed 2026-02-25 |
| 2025-09-30 | $14.69M 10-Q · filed 2025-11-05 | $34.85M derived: sum of 2 quarters · filed 2026-08-05 | $56.68M 10-Q · filed 2025-11-05 | $69.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $20.16M 10-Q · filed 2026-08-05 | $41.99M 10-Q · filed 2026-08-05 | $54.78M derived: sum of 3 quarters · filed 2026-08-05 | $66.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $21.83M 10-Q · filed 2026-05-06 | $34.62M derived: sum of 2 quarters · filed 2026-05-06 | $46.70M derived: sum of 3 quarters · filed 2026-05-06 | $55.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $24.87M derived: sum of 2 quarters · filed 2026-02-25 | $34.07M derived: sum of 3 quarters · filed 2026-02-25 | $45.24M 10-K · filed 2026-02-25 |
| 2024-09-30 | $12.08M 10-Q · filed 2025-11-05 | $21.28M derived: sum of 2 quarters · filed 2025-11-05 | $32.44M 10-Q · filed 2025-11-05 | $42.33M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $9.20M 10-Q · filed 2025-08-05 | $20.36M 10-Q · filed 2025-08-05 | $30.25M derived: sum of 3 quarters · filed 2026-02-25 | $41.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $11.17M 10-Q · filed 2025-05-05 | $21.05M derived: sum of 2 quarters · filed 2026-02-25 | $31.92M derived: sum of 3 quarters · filed 2026-02-25 | $41.31M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $20.76M derived: sum of 2 quarters · filed 2026-02-25 | $30.14M derived: sum of 3 quarters · filed 2026-02-25 | $42.59M 10-K · filed 2026-02-25 |
| 2023-09-30 | $10.88M 10-Q · filed 2024-11-06 | $20.26M derived: sum of 2 quarters · filed 2024-11-06 | $32.71M 10-Q · filed 2024-11-06 | $43.55M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $9.38M 10-Q · filed 2024-08-08 | $21.83M 10-Q · filed 2024-08-08 | $32.67M derived: sum of 3 quarters · filed 2025-02-28 | $48.08M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $12.45M 10-Q · filed 2024-05-09 | $23.29M derived: sum of 2 quarters · filed 2025-02-28 | $38.70M derived: sum of 3 quarters · filed 2025-02-28 | $52.92M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $26.25M derived: sum of 2 quarters · filed 2025-02-28 | $40.48M derived: sum of 3 quarters · filed 2025-02-28 | $48.27M 10-K · filed 2025-02-28 |
| 2022-09-30 | $15.41M 10-Q · filed 2023-11-09 | $29.64M derived: sum of 2 quarters · filed 2023-11-09 | $37.44M 10-Q · filed 2023-11-09 | $37.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $14.23M 10-Q · filed 2023-08-08 | $22.03M 10-Q · filed 2023-08-08 | $22.03M derived: sum of 3 quarters · filed 2024-02-29 | $22.03M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $7.80M 10-Q · filed 2023-05-08 | $7.80M derived: sum of 2 quarters · filed 2024-02-29 | $7.80M derived: sum of 3 quarters · filed 2024-02-29 | $7.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |